Royalty Pharma plc (NASDAQ:RPRX) Receives $41.80 Average Target Price from Brokerages

Royalty Pharma plc (NASDAQ:RPRX) has earned an average recommendation of “Moderate Buy” from the five research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $41.80.

Several analysts have issued reports on the stock. Morgan Stanley increased their target price on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, July 11th. StockNews.com downgraded Royalty Pharma from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. UBS Group lowered Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective for the company. in a research note on Monday, June 3rd. Finally, Bank of America decreased their price target on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating on the stock in a report on Friday, April 12th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Versant Capital Management Inc lifted its holdings in Royalty Pharma by 5,215.0% in the 2nd quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,043 shares during the period. Gladius Capital Management LP purchased a new stake in Royalty Pharma in the second quarter worth $32,000. Fidelis Capital Partners LLC bought a new stake in Royalty Pharma in the first quarter valued at $46,000. Allworth Financial LP increased its position in Royalty Pharma by 76.7% during the 4th quarter. Allworth Financial LP now owns 1,684 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 731 shares during the period. Finally, GAMMA Investing LLC raised its holdings in Royalty Pharma by 172.5% in the 1st quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 1,037 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

NASDAQ:RPRX opened at $28.68 on Friday. The business’s fifty day moving average is $26.95 and its 200 day moving average is $28.39. The firm has a market cap of $17.13 billion, a price-to-earnings ratio of 21.40, a PEG ratio of 3.74 and a beta of 0.46. The company has a debt-to-equity ratio of 0.62, a quick ratio of 12.52 and a current ratio of 12.52. Royalty Pharma has a 52-week low of $25.20 and a 52-week high of $31.66.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.02. Royalty Pharma had a return on equity of 22.94% and a net margin of 35.70%. The business had revenue of $568.00 million during the quarter, compared to analyst estimates of $671.45 million. During the same quarter in the previous year, the firm earned $1.60 EPS. Research analysts predict that Royalty Pharma will post 4.01 EPS for the current year.

Royalty Pharma Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 13th. Shareholders of record on Friday, August 16th will be given a dividend of $0.21 per share. The ex-dividend date of this dividend is Friday, August 16th. This represents a $0.84 annualized dividend and a yield of 2.93%. Royalty Pharma’s payout ratio is currently 62.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.